Insmed Incorporated
INSM
Rankning i aktier
#1109
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Aktiekurs
$95.88
Senast synkroniserad: 2026-10-20
Marknadsvärde
$20.94B
Förändring (1 dag)
0.61%
Förändring (1 år)
-42.00%
Land
US
Handel Insmed Incorporated (INSM)
Kategori
Healthcare
Historik för aktiesplit för Insmed Incorporated (INSM)
Aktien Insmed Incorporated (symbol: INSM) har genomgått totalt 2 aktiesplitar.
Den senaste spliten skedde den Mar 03, 2011.
En INSM-aktie köpt före Jul 31, 2000 motsvarar nu 0.025 INSM-aktier.
Den senaste spliten skedde den Mar 03, 2011.
En INSM-aktie köpt före Jul 31, 2000 motsvarar nu 0.025 INSM-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| 2011-03-03 | 1:10 | x0.1 | x0.025 |
| 2000-07-31 | 1:4 | x0.25 | x0.25 |
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
